Advertisement

Topics

Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy.

06:00 EDT 8th April 2011 | BioPortfolio

Summary of "Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy."

Bronchiectasis is a disease state defined by irreducible dilations of the airways. If they occur in diseases other than cystic fibrosis they are termed non-CF bronchiectasis. The common denominator is the increased risk of recurrent infections with bacteria, such as Staphylococcus aureus or Pseudomonas aeruginosa. Such infections are difficult to eradicate with systemic antibiotics because the structural abnormalities in the bronchial wall reduce their bactericidal effect at this level. An alternative to systemic antibiotics might be represented by inhaled formulations, which can be given in much lower doses and can be more effective. Previous studies demonstrated that inhaled gentamicin can reduce bacterial load and local infection in both cystic fibrosis and non-CF bronchiectasis. The study discussed in this paper demonstrates that long-term therapy with inhaled gentamicin can eradicate the infection or reduce the bacterial load, decrease the risk of subsequent infections and improve the quality of life in patients with non-CF bronchiectasis with a minimal risk of side effects.

Affiliation

University of Medicine and Pharmacy "Gr.T.Popa" Iasi, Pulmonary Disease University Hospital, Department of Medicine II - Pulmonary Disease, 30 Dr I Cihac Str, 700115 Iasi, Romania +0040232239408 ; Sabina.antonela.antoniu@pneum.umfiasi.ro.

Journal Details

This article was published in the following journal.

Name: Expert opinion on pharmacotherapy
ISSN: 1744-7666
Pages:

Links

DeepDyve research library

PubMed Articles [25251 Associated PubMed Articles listed on BioPortfolio]

Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.

Inhaled mannitol has beneficial effects on lung function, mucociliary clearance, quality of life and sputum properties. This trial examined the efficacy of inhaled mannitol in children with cystic fib...

Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know.

Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterised by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and...

Variants in the IL-8 gene and the response to inhaled bronchodilators in cystic fibrosis.

IL-8 (interleukin 8) protein promotes inflammatory responses, even in airways. The presence of IL-8 gene variants causes altered inflammatory responses and possibly varied responses to inhaled broncho...

Pain is an underestimated symptom in cystic fibrosis.

Life expectancy is increasing in cystic fibrosis and new aspects of the disease have to be taken into account in cystic fibrosis care.

New therapies for the prevention and treatment of exacerbations of bronchiectasis.

Exacerbations of bronchiectasis have a major impact on quality of life, healthcare costs, and long-term risk of complications. Preventing exacerbations is one of the major goals of treatment. Bronchie...

Clinical Trials [8625 Associated Clinical Trials listed on BioPortfolio]

The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis

The purpose of this study is to determine whether the daily inhalation of nebulised hypertonic saline (6%) will decrease the incidence of pulmonary exacerbations and increase the quality o...

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium

The purpose of the trial is to investigate if the use of inhaled colistimethate sodium administered twice daily for 12 months delays the time to the first pulmonary exacerbation compared t...

Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

The objective of this study is to assess the efficacy and safety of Salmeterol-Fluticasone combined inhaled therapy for non-CF bronchiectasis patients with chronic airflow obstruction. Mor...

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

No gold standard therapy exists for clearing mucus from the airways of patients with bronchiectasis. While rhDNase has a proven place in the treatment of CF, it failed to improve FEV1 in a...

Long Term Nebulised Gentamicin in Patients With Bronchiectasis

The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If g...

Medical and Biotech [MESH] Definitions

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)

A rehabilitation therapy for removal of copious mucus secretion from the lung of patients with diseases such as CHRONIC BRONCHITIS; BRONCHIECTASIS; PULMONARY ABSCESS; or CYSTIC FIBROSIS. The patient's head is placed in a downward incline (so the TRACHEA is inferior to the affected area) for 15- to 20-minute sessions.

A strain of mice widely studied as a model for cystic fibrosis. These mice are generated from embryonic stem cells in which the CFTR (cystic fibrosis transmembrane conductance regulator) gene is inactivated by gene targeting. As a result, all mice have one copy of this altered gene in all their tissues. Mice homozygous for the disrupted gene exhibit many features common to young cystic fibrosis patients, including failure to thrive, meconium ileus, and alteration of mucous and serous glands.

Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...